INDV vs MMED: fair value comparison
Indivior Pharmaceuticals, Inc. and MiniMed Group, Inc. · Updated 2026-10-19
MMED's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, INDV currently ranks higher by quality score.
| INDV | MMED | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $32.45 | $17.49 |
| 12-month range | $24.78–$41.83 | $12.00–$22.42 |
| Rank by discount to fair value | #17 of 108 Healthcare | — |
| Rank by quality score | #195 of 301 Healthcare | #196 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: INDV fair value analysis · MMED fair value analysis